Advertisement

Schmerztherapie in der Palliativmedizin

  • Otto Gehmacher
  • Rudolf Likar
  • Reinhard Sittl
  • Gebhard Mathis
Chapter
  • 3.9k Downloads

Zusammenfassung

Schmerzen sind ein sehr komplexes Geschehen: Neben den biologischen Ursachen bestehen psychische, soziale und spirituelle Einflüsse auf Schmerzempfindung und Schmerzverarbeitung (total-pain-Konzept). Bei entsprechend differenzierter Wahrnehmung all dieser Bereiche kann eine gezielte, multiprofessionelle Behandlung erfolgen. Die medikamentöse Schmerztherapie hat sich vielfältig durch neue Substanzen und Verabreichungsformen entwickelt. Deren Einsatz erfordert gute Kenntnisse. In manchen Situationen sind lokale invasive Maßnahmen zielführender als nur systemische Therapien. Das weite Feld der nichtmedikamentösen Schmerzbehandlung setzt eine gewisse Rezeptivität der Leidenden und eine Authentizität der Behandler voraus. Dann stehen viele Zugänge offen: physiotherapeutisch, psychotherapeutisch und verschiedene Entspannungsverfahren.

Literatur

Literatur zu Abschn. 4.1

  1. American Geriatrics Society Panel (2009) Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57(8):1331–1346Google Scholar
  2. Basmacioglu B, Aydinli I et al (2009) Effect of intravenous administration of paracetamol on morphine consumption in cancer pain control. Support Care Cancer 17(12):1475–1481Google Scholar
  3. Bennett MI, Laird B et al (2013) Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med 14:1681Google Scholar
  4. Bell RF, Eccleston C et al (2012) Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 11:CD003351Google Scholar
  5. Beubler E (2012) Kompendium der medikamentösen Schmerztherapie-Wirkungen, Nebenwirkungen und Kombinationsmöglichkeiten, 5. Aufl., Springer, Wien S. 23–25Google Scholar
  6. Bingel U, Schedlowski M (2015) Die Bedeutung von Placebomechansimen in der Schmerztherapie. In: Kress HG (Hrsg) Aktuelle Schmerzmedizin, economed Medizin, Hüthig Jehle Rehm, Landsberg/Lech, S. 9–12Google Scholar
  7. Breivik H, Cherny N et al (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20(8):1420–1433Google Scholar
  8. Branford R, Wighton E et al (2010) Principles of drug therapy: focus on opioids. In: Hanks G, Cherni NI, Christakis NA, Fallon M, Kassa S, Portenoy RK (Hrsg) Oxford textbook of palliative medicine, 4.Aufl. Oxford Univerity Press, Oxford, S. 493–505Google Scholar
  9. Brune K, Hinz B (2001) Nichtopioidanalgetika (antipyretische Analgetika und andere). In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie, 2.Aufl. Wissenschatliche Verlagsgesellschaft, Stuttgart, S. 233–253Google Scholar
  10. Cherny NI, Cleary J et al (2013) The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology. Ann Oncol 24(11):7–13Google Scholar
  11. Coxib and traditional NSAID Trialists’ (CNT) Collaboration (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769–779Google Scholar
  12. Dahan A, Yassen A, Romberg R et al (2006) Buprenorphine induces ceiling in respiratory depression but not in analgesia Dahan. Br J Anaesthesia 96(5):627–632Google Scholar
  13. Dale O, Moksnes K, Kaasa S (2011) European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med 25(5):494–503Google Scholar
  14. Davies AN, Dickman A et al (2009) Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13(4):331–338Google Scholar
  15. Derry S , Moore RA et al (2012) Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2012 Sept 12;(9):CD007400Google Scholar
  16. Eisenberg E, Marinangeli F et al (2005) Time to modify the WHO analgesic leader? Pain Clin Update 13(5):1–4Google Scholar
  17. Fallon MT (2013) Neuropathic pain in cancer. Br J Anesthesia 111(1):105–111Google Scholar
  18. Farquhar-Smith WP (2009) Do cannabinoids have a role in cancer pain management? Curr Opin Support Palliat Care 3(1):7–13Google Scholar
  19. FDA Public Health Advisory (2012). Risk of burns during MRI scans from transdermal drug patches with metallic backings. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm111313.htm
  20. Fine PG, Portenoy RK (2009) Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing »best practices« for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 38(3):418–425Google Scholar
  21. Finnerup NB, Sindrup SH et al (2010) The evidence for pharmacological treatment of neuropathic pain. Pain 150: 573–581Google Scholar
  22. Finnerup NB, Attal N et al (2015) Pharmacotherapy of neuropathic pain in adults: a systemic review and metaanalysis. The Lancet neurology 14(2):162–173Google Scholar
  23. Finniss DG, Benedetti F (2005) Mechanisms oft he placebo response and their impact on clinical trials and clinical practice. Pain 114(1-2):3–6Google Scholar
  24. Franceschi M, Scarcelli C et al (2008) Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 31(6):545–556Google Scholar
  25. Frohlich M, Gianotti A et al (2002) Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 93:647–648Google Scholar
  26. Indelicato RA, Portenoy RK (2002) Opioid rotation in the management of refractory cancer pain. J Cin Oncol 20:348–352Google Scholar
  27. Klaschik E, Clemens KE (2005) Opioide in der Tumorschmerztherapie – Wirksamkeit und Nebenwirkungen. Schmerz 19:395–403Google Scholar
  28. Klinger R, Schedlowski M et al(2010) Placebo Effekt in Schmerztherapie und -forschung. In: Kröner-Herwig B, Frettlöh J, Klinger R, Nilges P (Hrsg) Schmerzpsychotherapie, Springer, Berlin Heidelberg, S. 161–163Google Scholar
  29. Kraft B, Kress HG (2008) Cannabinoide in der Schmerz und Palliativmedizin. In: Kress HG (Hrsg) Aktuelle Schmerzmedizin, economed Medizin. Hüthig Jehle Rehm, Landsberg/Lech, S. 9–12Google Scholar
  30. Lamberts M, Lip GYH et al (2014) Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: A nationwide cohort study. Ann Intern Med 161:690–698Google Scholar
  31. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung (2015) Evidenztabellen 1.0, AWMF-Registernummer: 128 / 001OL, http://leitlinienprogramm-onkologie.de/Palliativmedizin.80.0.html
  32. Likar R, Sittl R (2002) Praxis der transdermlen Schmerztherapie. UNI-MED, BremenGoogle Scholar
  33. Loke YK, Trivedi AN et al (2008) Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 27:31–40Google Scholar
  34. Lux EA, Heine J (2011) Home care treatment of cancer pain patients with patient-controlled analgesia (PCA) Schmerz 25(6):663–667Google Scholar
  35. Maltoni M, Scarpi E et al (2005) A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 13(11):888–894Google Scholar
  36. Marinangeli F , Ciccozzi A et al (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 27(5):409–416Google Scholar
  37. Meier T, Wasner G et al (2003) Efficacy of lidocaine patch 5 % in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 106(1-2):151–158Google Scholar
  38. Mercadante S, Nabal M et al (2012) European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC, Lancet Oncol 13(2):e58–68Google Scholar
  39. Mercadante S, Porzio G et al (2012) Tapentadol in cancer pain management: a prospective open-label study. Pain 28(11):1775–1779Google Scholar
  40. Mishra S, Bhatnagar S et al (2012) A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 29:177–182Google Scholar
  41. Mou J, Paillard F et al (2013) Efficacy of Qutenza® (capsaicin) 8 % patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. 154(9):1632–1639Google Scholar
  42. Nabal M, Librada S et al (2011) The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med 26(4):305–312Google Scholar
  43. Nauck F, Radbruch L (2011) Systemische medikamentöse Schmerztherapie In: Aulbert E, Nauck F, Radbruch L (Hrsg) Lehrbuch der Palliativmedizin, 3. Auflage. Schattauer, Stuttgart, S. 175–205Google Scholar
  44. Nauck F, Klaschik E (2002) Schmerztherapie. Kompendium für Ausbildung und Praxis. Wissenschaftliche Verlagsgesellschaft StuttgartGoogle Scholar
  45. Okamoto Y, Tsuneto S et al (2013) Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer? Am J Hosp Palliat Care 30:450Google Scholar
  46. Okie S (2010) A Flood of Opioids, a Rising Tide of Deaths. N Engl J Med 363(21):1981–1985Google Scholar
  47. Pasero C (2007) IV opioid range orders for acute pain management. AJN 107(2):52–59Google Scholar
  48. Paulsen AN, Kaasa S et al (2013) Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manage 46:96Google Scholar
  49. Portenoy RK, Ahmed E et al (2015) Cancer pain management: Adjuvant analgesics (coanalgesics). UpToDateGoogle Scholar
  50. Portenoy RK, Ahmed E et al (2014) Cancer pain management: Use of acetaminophin and nonsteroidal antiinflammatory drugs. UptoDateGoogle Scholar
  51. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41(3):273–281Google Scholar
  52. Portenoy RK, Ahmet E (2013) Adjuvant Analgesics in Management of Cancer-Related Neuropathic Pain, Encyclopedia of Pain, pp 71–75Google Scholar
  53. Radbruch L, Sabatowski R et al (2001) Transdermal fentanyl fort he management of cancer pain: a survey of 1005 patients. Palliat Med 15:309–321Google Scholar
  54. Rezende RM, França DS et al ( 2008) Different mechanisms underlie the analgesic actions of paracetamol and dipyrone in a rat model of inflammatory pain. Br J Pharmacol 153(4):760–768Google Scholar
  55. Rogosch T, Sinning C et al (2012) Novel bioactive metabolites of dipyrone (metamizol). Bioorg Med Chem 20(1):101–107Google Scholar
  56. Saunders CM (1978) The Management of terminal malignant disease,. Edward Arnold, LondonGoogle Scholar
  57. Schick V, Schulz HJ (2010) Nichtsteroidale Antirheumatika und Gastrointestinaltrakt Gastroenterologie 5:461–472Google Scholar
  58. Schubert I, Ihle P et al (2013) Zunahme der Opioidverordnungen in Deutschland zwischen 2000 und 2010: Eine Studie auf der Basis von Krankenkassendaten, Dtsch Arztebl Int 110(4):45–51Google Scholar
  59. Smith HS, Peppin JF (2014) Toward a systematic approach to opioid rotation. J Pain Res 7:589–608Google Scholar
  60. Stockler M, Vardy J et al (2004) Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 22(16):3389–3394Google Scholar
  61. Svendsen KB, Andersen S et al (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9(2):195–206Google Scholar
  62. Tassinari D, Sartori S et al (2008) Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 11(3):492–501Google Scholar
  63. Tremont-Lukats IW, Challapalli V et al (2005) Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg 101:1738Google Scholar
  64. Twycross R (1999) Opioids. In: Wall PD, Melzack R (Hrsg) Textbook of pain, 4. Aufl. Churchill Livingston, Edinburgh London, S. 1187–1214Google Scholar
  65. Vaile JH, Davis P (1998) Topical NSAIDs for musculoskeletal conditions. Drugs 56(5):793–799Google Scholar
  66. Van den Beuken-vanEverdingen MHJ, de Rijke JM et al (2007) Prevalence of pain in patients with cancer:a systemic review of the past 40 years. Ann Oncology 18(9):1437–1449Google Scholar
  67. Vargas-Schaffer G (2010) Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 56(6):514–517Google Scholar
  68. Weber LM, Ghafoor VL et al (2008) Implementation of standard order sets for patient-controlled analgesia. Am J Health Syst Pharm 65(12):1184–1191Google Scholar
  69. WHO (1996) Cancer pain relief, with a guide to opioid availability. World Health Organization, GenevaGoogle Scholar
  70. Wong MH, Stockler MR et al (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474Google Scholar
  71. Zech DF, Grond S et al (1995) Validation of World Health Organization guidelines for cancer pain relief: a 10 year prospective study. Pain 63(1):65–76Google Scholar
  72. Zeppetella G, Davies AN (2013) Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 10:CD004311Google Scholar

Literatur zu Abschn. 4.2

  1. Amesbury B, O’Riordan J (1999) The use of interpleural analgesia using bupivacaine for pain relief in advanced cancer. Palliat Med 13(2):153–158Google Scholar
  2. Baker L, Lee M, Regnard C et al (2004) Evolving spinal alagesia practice in palliative Care. Palliat Med 18:507–515Google Scholar
  3. Ballantyne JC et al (1996) Comparative efficacy of epidural, subarachnoid and Intracerebro-ventricular opioids in patients with pain due to cancer. Regional Anesthesia 21(6):542–556Google Scholar
  4. Cleary JF (2000) Cancer pain management. Cancer Control 7(2):120–131Google Scholar
  5. Deer TR, Prager J, Levy R et al (2012) Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel; NeuromodulationGoogle Scholar
  6. Eisenberg E, Carr DB, Chalmers TC (1995) Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis Anesth Anal. 1995 Feb;80(2):290-5Google Scholar
  7. Lema MJ (2001) Invasive analgesia techniques for advanced cancer pain. Surg Oncol Clin N Am 10(1):127–136Google Scholar
  8. Lynch J, Zech D, Grond S (1992) The role of intrathecal neurolysis in the treatment of cancer-related perianal and perineal pain. Palliat Med 6(2):140–145Google Scholar
  9. Mummenthaler M et al (Hrsg) (1990)Treatment of Chronic Pain: Possibilities, Limitations and Long-term Follow-Up. Harwood, LondonGoogle Scholar
  10. Nagels W, Pease N, Bekkering G (2013) Celiac Plexus Neurolysis for Abdominal Cancer Pain: A systematic Review. Pain Medicine 14:1140–1163Google Scholar
  11. Nitescu P, Applegren L, Lindler L (1990) Epidural versus intrathecal morphine bupivacaine: Assessment of consecutive treatments in advanced cancer pain. J Pain Syndrom Manag 5:18–26Google Scholar
  12. Plancarte R, de Leon-Casasola OA, El-Helaly M et al (1997) Neurolytic superior hypogastric plexus block for chronic pain associated with cancer. Reg Anaesth 22:562–568Google Scholar
  13. Raphael J, Hester J, Ahmedzai S et al (2010) Cancer Pain: Part 2: Physical, Interventional and Complimentary Therapies, Management in the Community; Acute , Treatment-Related and Complex Cancer Pain; A Perspective from the British Pain Society Endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Medicine 11:872–896Google Scholar
  14. Shankar H, Khatri V, Eastwood D (2010) Retrospektive Comparison of Ultrasound and Fluoroscopie Image Guidance for Intercostal Steroid Injections. Pain Practice 10(4):312–317Google Scholar
  15. Smith TJ, Staats PS, Deer T et al (2002) Implantable drug delivery systems study group. Randomised clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain; impact on pain, drug related toxicity and survival. J Clin Oncol 20:4040–4049Google Scholar
  16. Vissers KCP, van den Brand MWM, Jacobs J et al (2013) Palliative Medicine Update: A Multidisciplinary Approach. Pain Practice 13(7):576–588Google Scholar
  17. Williams JE, Louw G, Towlerton G (2000) Intrathecal pumps for giving opioids in chronic pain: A systematic review. Health Technol Assess 4(32):1–65Google Scholar
  18. Wong FCS, Lee TW, Yuen KK et al (2007) Intercostal nerve blockade for cancer pain: Effectiveness and selection of patients. Hong Kong Med J 13:266–270Google Scholar
  19. Yamamuro M, Kusaka K, Kato M, Takahashi M (2000) Celiac Plexus Block in Cancer Pain Management. Tohoku J Exp Med 192:1–18Google Scholar
  20. Yan BM, Myers RP (2007) Neurolytic celiac plexus block for pain control in unresectable pancreatic. Cancer Am J Gastroenterol 102(2):430–438Google Scholar

Literatur zu Abschn. 4.3

  1. AWMF (2015) Leitlinienprogramm Onkologie/S 3-Leitlinie Palliativmedizin. AWMF-Registernummer: 128/001OL, S. 60Google Scholar
  2. Basler HD, Kröner-Herwig B et al (2003) Pychologische Schmerztherapie 5. Aufl. Springer, HeidelbergGoogle Scholar
  3. Bernatzky G, Presch M, Anderson M, Panksepp J ( 2011) Emotional foundations of music as a non-pharmacological pain management tool in modern medicine. Neuroscience and Biobehavioral Reviews 35:1889-99Google Scholar
  4. Bernatzky G, Hesse HP ( 2012) Musik in der Palliativmedizin. In: Bernatzky G., Sittl R., Likar R. (Hrsg.): Schmerzbehandlung in der Palliativmedizin 3., überarb Aufl Springer Wien S. 229–234Google Scholar
  5. Bernatzky G, Wendtner F, Flock T (2014) Entspannung bei Stress 2, Wohlfühl-CD zum Entschleunigen, Entspannen und Regenerieren. Musik mit Entspannungsanleitung; Audio CD © Spield.: 51:16 min, Verlag clara luminaGoogle Scholar
  6. Bernstein DA, Borkovec TD (2000) Entspannungstraining. Handbuch der progressiven Muskelentspannung nach Jacobson Klett-Cotta, StuttgartGoogle Scholar
  7. Erickson MH (1959) Hypnosis in painful terminal illness. Am J Clin Hypn;1:117–21Google Scholar
  8. Gatterer G (2009) Progressive Muskelentspannung nach Jacobson. In: Likar R, Bernatzky G, Märkert D, Ilias W (Hrsg) Schmerztherapie in der Pflege, Springer WienGoogle Scholar
  9. Jensen KB, Petrovic P, Kerr C et al ( 2014) Sharing pain relief: Neural correlates od physicians during treatment of patients. Mol Psychiatry19:392–398Google Scholar
  10. Kaiser-Rekkas A (2009) Hypnosetherapie beim Schmerz. In: Likar R, Bernatzky G. Schmerztherapie in der Pflege. Springer Wien NewYork; 241–247Google Scholar
  11. Kant I (1998) Kritik der reinen Vernunft. Meiner Verlag, Hamburg 1998,Google Scholar
  12. Nieland P (2009) Physiotherapie in der Palliativmedizin. Z Palliativmed 10:85–101Google Scholar
  13. Petrovic P, Kalso E, Petersson KM, Ingvar M ( 2002) Placebo and Opioid Analgesia – Imaging a Shared Neuronal Network. Science 295:1737–1740Google Scholar
  14. Petzold H (2004)Integrative Therapie. Modelle, Theorien und Methoden einer schulenübergreifenden Psychotherapie, 3 Bände, 2. Auflage, Junfermann, PaderbornGoogle Scholar
  15. Revenstorf D (2006) Expertise zur Beurteilung der wissenschaftlichen Evidenz des Psychotherapieverfahrens Hypnotherapie entsprechend den Kriterien des Wissenschaftlichen Beirats Psychotherapie. Hypnose ZHH Band 1 und 2Google Scholar
  16. Schultz JH (1932) Das autogene Training (konzentrative Selbstentspannung). Versuch einer klinisch-praktischen Darstellung. Thieme, LeipzigGoogle Scholar
  17. Schulze W (2013) Hypnose und Hypnotherapie in der Palliativmedizin – Symptombehandlung und spirituelle Begleitung. Z. Palliativmed 14:59–72Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  • Otto Gehmacher
    • 1
  • Rudolf Likar
    • 2
  • Reinhard Sittl
    • 3
  • Gebhard Mathis
    • 4
  1. 1.Landeskrankenhaus HohenemsHohenemsÖsterreich
  2. 2.Vorstand der Abteilung für Anästhesie und IntensivmedizinKlinikum Klagenfurt am WörtherseeKlagenfurtÖsterreich
  3. 3.FürthDeutschland
  4. 4.RankweilÖsterreich

Personalised recommendations